Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-Well 2: Phase 3 randomized double-blind study of bepirovirsen in NA-treated chronic hepatitis B
jRCT2061220074Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2022
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing Bepirovirsen arm with Placebo arm (2 arms). Primary endpoint: Functional cure with baseline HBsAg ≤1000 IU/mL. Started Dec 2022; status: completed.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on jRCT2061220074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220074.